Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...
Regenxbio: 2 Major Catalysts Could Change The Investment Case
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript
REGENXBIO (NASDAQ:RGNX) Q3 2026: Narrower Loss Offsets Revenue Miss as Shares Rise Premarket
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
Regenxbio: Q3 Earnings Snapshot
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
Regenxbio Q3 2026 Earnings Call Transcript
Regenxbio Q3 EPS $(0.62) Beats $(1.26) Estimate, Sales $9.162M Miss $10.868M Estimate
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
Full Transcript: Regenxbio Q2 2026 Earnings Call
Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22
Regenxbio stock gains on positive gene therapy trial data
Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.